MedDataX Logo

Disruption of Memory Reconsolidating as a Treatment for Panic Disorder

NCT ID: NCT02631694

Last Updated: 2015-12-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-30

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Animal and human fear conditioning studies have repeatedly shown that administering propranolol before or after retrieval of a previously acquired fear results in an elimination of the fear expression. This approach, known as disruption of fear memory reconsolidation, is a promising new avenue for treating anxiety disorders. The present study aims to test its efficacy in patients with panic disorder.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Panic Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fear reactivation with propranolol

Group Type EXPERIMENTAL

Propranolol

Intervention Type DRUG

Intake of propranolol pill (40 milligram)

Carbon dioxide

Intervention Type OTHER

Inhalation of 35% carbon dioxide

Fear reactivation with placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Intake of placebo pill (40 milligram)

Carbon dioxide

Intervention Type OTHER

Inhalation of 35% carbon dioxide

No fear reactivation with propranolol

Group Type PLACEBO_COMPARATOR

Propranolol

Intervention Type DRUG

Intake of propranolol pill (40 milligram)

Compressed air

Intervention Type OTHER

Inhalation of air

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propranolol

Intake of propranolol pill (40 milligram)

Intervention Type DRUG

Placebo

Intake of placebo pill (40 milligram)

Intervention Type DRUG

Carbon dioxide

Inhalation of 35% carbon dioxide

Intervention Type OTHER

Compressed air

Inhalation of air

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* a primary diagnosis of panic disorder according to DSM-V
* written approval of an independent physician for participation

Exclusion Criteria

* other relevant treatment for panic disorder at the time of study - e.g., Cognitive Behavioral Therapy (CBT)
* diagnosis of depression
* diagnosis of psychosis
* use of psychotropic medication
* history of pulmonary diseases
* metabolic acidosis
* history of cardiovascular diseases
* heart problems among first-degree relatives
* heart rate (HR) \< 60
* blood pressure (BP) \< 90-60 or BP \> 170-100
* history of black-outs or fainting
* diabetes
* liver or kidney diseases
* hyperactive production of thyroid hormones
* epilepsy
* any medication contra-indicative of the use of propranolol
* pregnancy
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

VU University of Amsterdam

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mrs. M. Kindt

Professor of Experimental and Clinical Psychology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Merel Kindt, Prof. dr.

Role: PRINCIPAL_INVESTIGATOR

University of Amsterdam

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Arnold A.P. van Emmerik, PhD

Role: CONTACT

Phone: 0031205258604

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MKAEWC1

Identifier Type: -

Identifier Source: org_study_id